ONXX Onyx Pharmaceuticals, Inc. (MM)

124.70

0.00 (0.00%)

15 Jul 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Onyx Pharmaceuticals, Inc. (MM)	NASDAQ:ONXX	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	124.70						0	01:00:00

Onyx Pharmaceuticals (ONXX) - Bull of the Day

05/12/2012 12:00am

Zacks

We are upgrading Onyx Pharmaceuticals (ONXX) to Outperform based on the company's strong third quarter results and improving prospects. Onyx reported solid third quarter results with revenues increasing 19.3% to $89.5 million, well above the Zacks Consensus Estimate of $81 million.

Third quarter 2012 loss of $0.89 per share was narrower than the Zacks Consensus Estimate of a loss of $1.08. Recently launched Kyprolis is off to a solid start and the strong ramp should continue.

Loss estimates for both 2012 and 2013 have gone down and the Zacks Rank has moved to #2 (short-term Buy rating) from 3 (short-term Hold rating). With two back-to-back product approvals to its credit, Onyx has successfully transformed itself from a one-product company to a multiple-product company.

ONYX PHARMA INC (ONXX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research